ONI BioPharma Announces Exclusive Agreement
with Garden of Life, Inc., for Use of ProBiora3™
This groundbreaking oral care probiotic ingredient will be used in Garden of Life’s oral healthcare products
(Alachua, FL) The Florida-based biotechnology firm ONI BioPharma has announced an agreement to provide Garden of Life its revolutionary oral-care probiotic ingredient, ProBiora3™, for use in a variety of high-grade oral health products. ProBiora3™ is a patented probiotic formula containing a blend of three bacteria that are natural residents in healthy mouths. Garden of Life is a leader in whole food nutrition, probiotics and digestive-related products. It’s the 14th largest brand in the Healthy Foods Channel.
“Garden of Life is a leading innovator in the natural products industry,” said Stanley Stein, ONI BioPharma’s CEO and president. “This new relationship will dramatically increase the use of ProBiora3™ in a host of health and wellness products. It’s a terrific opportunity to have an enormous impact on oral health and wellness worldwide.”
Garden of Life President Brian Ray said the company’s mission is to provide the most effective nutritional products in the world for its customers. “This agreement reaffirms our longstanding commitment to combine the best of nature and science,” he said. “ProBiora3™ is the result of 25 years of study. It’s breakthrough technology like this that keeps Garden of Life products on the leading edge of our industry.”
ProBiora3™ is a patented, complete oral-care probiotic ingredient containing a blend of three bacteria that are natural residents in healthy mouths. It is the first complete oral care probiotic blend that supports tooth and gum health, freshens breath and whitens teeth.
ProBiora3™ was developed by Dr. Jeffrey Hillman, D.M.D., Ph.D., and chief scientific officer at ONI BioPharma. It’s the result of more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida. The technology has only recently become available for the general public.
“ONI BioPharma is committed to developing and licensing technologies and partnering with industry leaders to create novel therapies and diagnostic products,” said Stein. “This is a great step forward to promoting oral health on a worldwide scale.”
About ONI BioPharma
Oragenics, Inc. (d/b/a ONI BioPharma Inc.) is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The company is located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville.
